238 related articles for article (PubMed ID: 34432892)
21. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
[TBL] [Abstract][Full Text] [Related]
22. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
[TBL] [Abstract][Full Text] [Related]
23. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
[TBL] [Abstract][Full Text] [Related]
24. SGLT-2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient.
Ritchie DT; Dixon J
BMJ Case Rep; 2022 Sep; 15(9):. PubMed ID: 36113958
[TBL] [Abstract][Full Text] [Related]
25. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Menghoum N; Oriot P; Hermans MP; Mariage JL
Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
[TBL] [Abstract][Full Text] [Related]
26. SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
Griffin TP; Dinneen SF
Ann Intern Med; 2020 Oct; 173(8):JC40. PubMed ID: 33075260
[TBL] [Abstract][Full Text] [Related]
27. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
[TBL] [Abstract][Full Text] [Related]
28. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
29. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
30. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
Thiruvenkatarajan V; Meyer EJ; Nanjappa N; Van Wijk RM; Jesudason D
Br J Anaesth; 2019 Jul; 123(1):27-36. PubMed ID: 31060732
[TBL] [Abstract][Full Text] [Related]
31. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Ahmed M; McKenna MJ; Crowley RK
Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
[TBL] [Abstract][Full Text] [Related]
32. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
Douros A; Lix LM; Fralick M; Dell'Aniello S; Shah BR; Ronksley PE; Tremblay É; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ernst P; Filion KB;
Ann Intern Med; 2020 Sep; 173(6):417-425. PubMed ID: 32716707
[TBL] [Abstract][Full Text] [Related]
33. Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery.
Pontes JPJ; de Melo CS; Arantes FBB; de Souza Ramos JTG; Módolo NSP; Navarro E Lima LH
J Clin Anesth; 2021 Aug; 71():110201. PubMed ID: 33647525
[No Abstract] [Full Text] [Related]
34. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
[TBL] [Abstract][Full Text] [Related]
35. Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors.
Pikielny PR; Lurie TH; Rabia R; Twito O; Rosenblum RH; Yoseph LB
Endocr Pract; 2023 Sep; 29(9):686-691. PubMed ID: 37442436
[TBL] [Abstract][Full Text] [Related]
36. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
37. Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series.
Puls HA; Haas NL; Franklin BJ; Theyyunni N; Harvey CE
Am J Emerg Med; 2021 Jun; 44():11-13. PubMed ID: 33571749
[TBL] [Abstract][Full Text] [Related]
38. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
[TBL] [Abstract][Full Text] [Related]
39. [SGLT 2 inhibitors in Type 1 diabetes].
Stougaard EB; Amadid H; Søndergaard E; Jørgensen ME; Persson F; Rossing P
Ugeskr Laeger; 2020 Aug; 182(35):. PubMed ID: 32829747
[TBL] [Abstract][Full Text] [Related]
40. Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events.
Alkabbani W; Pelletier R; Gamble JM
Am J Epidemiol; 2021 Aug; 190(8):1572-1581. PubMed ID: 33751032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
